In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates

A study assessing the in vitro activity of cefiderocol against carbapenem resistant clinical isolates compared to select antimicrobial agents, including colistin, found that 58.4% of the 77 isolates belonged to Enterobacterales, followed by P.aeruginosa and Acinetobacter spp. Three out of 45 Enterobacterales isolates were found resistant to cefiderocol, while all isolates were intermediate sensitive for colistin. Tigecycline showed good activity against Enterobacterales, followed by aztreonam. Cefiderocol is not yet available in India.